ๅฟ ้่่ช้ ธ (Omega-3 / Omega-6)
ๅฟ ้่่ช้ ธ (EFAs) ๆฏๅ็ฉ้ซๅ ง็กๆณ่ช่กๅๆใๅฟ ้ ้้้ฃฒ้ฃๆๅ็ๅคไธ้ฃฝๅ่่ชใๅจ็ธ้ซๅญธไธญ๏ผไธป่ฆๅฉ็จๅ ถๆ็ผ็็นๆงไพ็ถญๆ็ฎ่ใๅฟ่ก็ฎกใ่ ่ๅ้็ฏๅฅๅบทใ * **Omega-3 ่่ช้ ธ** (EPA, DHA) ้ๅธธ่ๅ่ชๆตทๆด็็ฉ (้ญๆฒน)๏ผไปฅๆธ่ผ็ผ็ๅๆ่ๅใ * **Omega-6 ่่ช้ ธ** (ไบ้บปๆฒน้ ธ) ๅฐๆผ็ถญๆ่กจ็ฎ่่ณชๅฑ้ๅๆฏ้ซฎๅ่ณช่ณ้้่ฆใ > **่จๅบ่ฆ้ป๏ผ** ็พไปฃๅฏต็ฉ้ฃฒ้ฃ้ๅธธๅซๆ้ๅค็ Omega-6๏ผๅ ๆญค่ฃๅ Omega-3 ๅฐๆผๆงๅถ้ชจ้็ฏ็ใ็ฐไฝๆง็ฎ่็ๅๆ ขๆง่ ็ ็ญ็ผ็ๆง็พ็ ้ๅธธๆ็ใ
ไฝ็จๆฉๅถ: **Omega-3s (EPA/DHA)** compete with arachidonic acid (an Omega-6) for the enzymes **cyclooxygenase (COX)** and **lipoxygenase (LOX)**. * EPA/DHA โ COX/LOX โ Production of less inflammatory eicosanoids (e.g., 3-series prostaglandins and 5-series leukotrienes) instead of the highly inflammatory 2-series prostaglandins and 4-series leukotrienes. * **Omega-6s (Linoleic Acid)** โ incorporated into the stratum corneum โ improves water barrier function and reduces transepidermal water loss (TEWL).
็ตฆ่ฅ้ๅพ
็ฆๅฟ็
- Patients with a history of pancreatitis
- Patients with bleeding disorders (use with caution)
ไธ่ฏๅๆ
- Gastrointestinal upset (diarrhea, vomiting)
- Weight gain
- Altered platelet function (high doses)
- Pancreatitis (rare, in susceptible individuals due to fat content)
่ฅ็ฉ็ธไบไฝ็จ
- Anticoagulants (e.g., Heparin, Warfarin) ยท May increase risk of bleeding due to altered platelet aggregation
- NSAIDs ยท Synergistic anti-inflammatory effect (often beneficial, allowing for lower NSAID doses)
็ฃๆธฌ
- Clinical response (improvement in coat, mobility, or renal values)
- Fecal consistency
- Signs of bleeding (if on high doses)
้้
Acute overdose may cause significant gastrointestinal distress, including vomiting, diarrhea, and potentially pancreatitis. Chronic massive overdose may lead to coagulopathies or delayed wound healing. Treatment is supportive.
VetSheet ่ฅ็ฉๅ่ไพๆ็็ธ้ซๅฐๆฅญไบบๅกไฝ่จๅบๆฑบ็ญ่ผๅฉไน็จ,ไธ่ฝๅไปฃๅฐๆฅญๅคๆทๆๅป ๆนๆๆฐ่ฅๅ่ชชๆๆธใ